CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview at the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2023, at 7:30 a.m. PT (10:30 a.m. ET). The presentation will be available for live webcast and replay on CTI's website. The company specializes in targeted therapies for blood-related cancers, with an FDA-approved product, VONJO^®, for treating myelofibrosis in certain patients. Continued approval may depend on clinical benefit verification through ongoing studies.

SEATTLE, Jan. 5, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco.

Presentation details:

Event: 41^st Annual J.P. Morgan Healthcare Conference 
Date: Thursday, January 12, 2023 
Time: 7:30 a.m. PT/10:30 a.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.

We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO^® (pacritinib), a JAK2 and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO^® is a registered trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts: 
Argot Partners 
+212-600-1902 
cti@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301713528.html

SOURCE CTI BioPharma Corp.

FAQ

When is CTI BioPharma presenting at the J.P. Morgan Healthcare Conference?

CTI BioPharma will present on January 12, 2023, at 7:30 a.m. PT.

Where can I watch the CTI BioPharma presentation?

The presentation can be watched live and replayed on CTI BioPharma's website.

What product does CTI BioPharma have approved by the FDA?

CTI BioPharma's FDA-approved product is VONJO^® (pacritinib).

What is VONJO^® used for?

VONJO^® is used for treating adults with myelofibrosis who have severe thrombocytopenia.

What is the significance of the PACIFICA study for CTI BioPharma?

The PACIFICA study is a Phase 3 trial required for continued approval of VONJO^® in certain myelofibrosis patients.